Imfinzi and Imfinzi plus tremelimumab delayed
This announcement contains inside information 28 October 2019 15:15 GMT Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer POSEIDON included both non-squamous and squamouspatients and a broad choice of standard chemotherapy options AstraZeneca today announced positive progression-free survival (PFS) results for Imfinzi(durvalumab) and tremelimumab, an anti-CTLA4 antibody, when added to chemotherapy, from the Phase III POSEIDON trial in previously-